177 related articles for article (PubMed ID: 24840555)
1. APOBEC3 signature mutations in chronic lymphocytic leukemia.
Rebhandl S; Huemer M; Gassner FJ; Zaborsky N; Hebenstreit D; Catakovic K; Grössinger EM; Greil R; Geisberger R
Leukemia; 2014 Sep; 28(9):1929-32. PubMed ID: 24840555
[No Abstract] [Full Text] [Related]
2. APOBEC3-mediated restriction of RNA virus replication.
Milewska A; Kindler E; Vkovski P; Zeglen S; Ochman M; Thiel V; Rajfur Z; Pyrc K
Sci Rep; 2018 Apr; 8(1):5960. PubMed ID: 29654310
[TBL] [Abstract][Full Text] [Related]
3. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Kim EY; Lorenzo-Redondo R; Little SJ; Chung YS; Phalora PK; Maljkovic Berry I; Archer J; Penugonda S; Fischer W; Richman DD; Bhattacharya T; Malim MH; Wolinsky SM
PLoS Pathog; 2014 Jul; 10(7):e1004281. PubMed ID: 25080100
[TBL] [Abstract][Full Text] [Related]
4. Quantitative RT-PCR analysis of activation-induced cytidine deaminase expression in tissue samples from mantle cell lymphoma and B-cell chronic lymphocytic leukemia patients.
Guikema JE; Rosati S; Akkermans K; Bende RJ; van Noesel CJ; van Krieken JH; Hansmann ML; Schuuring E; Kluin PM
Blood; 2005 Apr; 105(7):2997-8; discussion 2998-9. PubMed ID: 15781912
[No Abstract] [Full Text] [Related]
5. Clinical Implications of APOBEC3-Mediated Mutagenesis in Breast Cancer.
Roelofs PA; Martens JWM; Harris RS; Span PN
Clin Cancer Res; 2023 May; 29(9):1658-1669. PubMed ID: 36478188
[TBL] [Abstract][Full Text] [Related]
6. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Swanton C; McGranahan N; Starrett GJ; Harris RS
Cancer Discov; 2015 Jul; 5(7):704-12. PubMed ID: 26091828
[TBL] [Abstract][Full Text] [Related]
7. Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses.
Rulli SJ; Mirro J; Hill SA; Lloyd P; Gorelick RJ; Coffin JM; Derse D; Rein A
J Virol; 2008 Jul; 82(13):6566-75. PubMed ID: 18448535
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis.
Maciejowski J; Chatzipli A; Dananberg A; Chu K; Toufektchan E; Klimczak LJ; Gordenin DA; Campbell PJ; de Lange T
Nat Genet; 2020 Sep; 52(9):884-890. PubMed ID: 32719516
[TBL] [Abstract][Full Text] [Related]
9. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.
Kanu N; Cerone MA; Goh G; Zalmas LP; Bartkova J; Dietzen M; McGranahan N; Rogers R; Law EK; Gromova I; Kschischo M; Walton MI; Rossanese OW; Bartek J; Harris RS; Venkatesan S; Swanton C
Genome Biol; 2016 Sep; 17(1):185. PubMed ID: 27634334
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases.
Ng JCF; Quist J; Grigoriadis A; Malim MH; Fraternali F
Nucleic Acids Res; 2019 Feb; 47(3):1178-1194. PubMed ID: 30624727
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3 induces mutations during repair of CRISPR-Cas9-generated DNA breaks.
Lei L; Chen H; Xue W; Yang B; Hu B; Wei J; Wang L; Cui Y; Li W; Wang J; Yan L; Shang W; Gao J; Sha J; Zhuang M; Huang X; Shen B; Yang L; Chen J
Nat Struct Mol Biol; 2018 Jan; 25(1):45-52. PubMed ID: 29323274
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion.
Nowarski R; Kotler M
Cancer Res; 2013 Jun; 73(12):3494-8. PubMed ID: 23598277
[TBL] [Abstract][Full Text] [Related]
13. The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond.
Kinoshita K; Nonaka T
Int J Hematol; 2006 Apr; 83(3):201-7. PubMed ID: 16720548
[TBL] [Abstract][Full Text] [Related]
14. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
Petljak M; Green AM; Maciejowski J; Weitzman MD
Nat Genet; 2022 Nov; 54(11):1599-1608. PubMed ID: 36280735
[TBL] [Abstract][Full Text] [Related]
15. Perturbation of base excision repair sensitizes breast cancer cells to APOBEC3 deaminase-mediated mutations.
Shen B; Chapman JH; Custance MF; Tricola GM; Jones CE; Furano AV
Elife; 2020 Jan; 9():. PubMed ID: 31904337
[TBL] [Abstract][Full Text] [Related]
16. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
17. [Molecular evolution of physiologically functioning anti-retroviral APOBEC3 deaminases].
Miyazawa M
Uirusu; 2012 Jun; 62(1):27-38. PubMed ID: 23189822
[TBL] [Abstract][Full Text] [Related]
18. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
19. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3 enzymes restrict marginal zone B cells.
Beck-Engeser GB; Winkelmann R; Wheeler ML; Shansab M; Yu P; Wünsche S; Walchhütter A; Metzner M; Vettermann C; Eilat D; DeFranco A; Jäck HM; Wabl M
Eur J Immunol; 2015 Mar; 45(3):695-704. PubMed ID: 25501566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
